Presbia — Piper Jaffray Healthcare Conference 2015
24 slides from Presbia's conference presentation, Nov 30, 2015

Slide 1: Piper Jaffray Healthcare Conference December 2015 Investor Presentation
Piper Jaffray Healthcare Conference December 2015 Investor Presentation

Slide 2: Disclosure
Disclosure To the extent statements contained in this presentation are not descriptions of historical facts regarding Presbia PLC and its subsidiaries (collectively “Presbia,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward

Slide 3: Business Highlights
Business Highlights Large, Underserved Presbyopia Opportunity Best-in-Class Microlens Technology Refractive corneal inlay restores reading vision—average 6 lines of improvement Wide range of lens size refractive powers to offer patients a customized therapy Compatible with other ophthalmic surgical

Slide 4: Presbyopia Surgery is the Missing Piece in Refractive Surgery
Presbyopia Surgery is the Missing Piece in Refractive Surgery Hit hard by flat-to-declining LASIK procedure volumes, overcapacity, and LASIK procedure price erosion Highly receptive to new private pay presbyopia procedure requiring no capital outlay Refractive Surgery Centers No capital expenditure

Slide 5: Presbyopia: A Loss of Near Vision Affecting the Majority of People over 40
Presbyopia A Loss of Near Vision Affecting the Majority of People over the Age of 40 The Inconvenience of Presbyopia Glasses off / on; lost glasses (can’t find them when you need them), etc. Hassle of daily maintenance of contact lenses, especially among active people Difficulty seeing text/images o

Slide 6: Large, Underserved and Growing Market Opportunity
Large, Underserved And Growing Market Opportunity Demographic-Driven Market Growth 1.8 Billion Presbyopes (billions) Source: 2013 Market Scope. United States (113) Western Europe (165) Latin America (140) China (423) India (249) Rest of World (542) Other Wealthy Nations (71) Japan (58) (millions)

Slide 7: Clear U.S. Regulatory Pathway
Clear U.S. Regulatory Pathway Targeted U.S. IDE Regulatory Pathway – Presbia Flexivue Microlens™ Q3 2014: 75th patient treated (6 sites) Q2 2015: Continuance of enrollment in U.S. (346 total subjects at 11 sites) Q4 2018: Receive PMA approval Submit Annual Report to FDA that includes data for all su

Slide 8: U.S. Pivotal Trial
U.S. Pivotal Trial January 2015: Submitted interim safety report to FDA, which included 6-month data on 52 subjects (a total of 75 subjects were implanted at six investigational sites in the first stage of this trial) February 2015: Approved to begin 2nd stage enrollment; we were permitted to enroll

Slide 9: Focused Commercialization Strategy
Focused Commercialization Strategy Phase 1 Asia Pacific South Korea Europe Germany Key Accounts Australia/New Zealand Ireland Netherlands Canada Phase 2 Asia Pacific Expansion as warranted: Japan, Malaysia, Singapore, Thailand Europe Expansion as warranted: Spain, Italy, UK, other Phase 3 North Amer

Slide 10: Phase 1 Focus Markets: Asia Pacific & Europe
Phase 1 Focus Markets Asia Pacific & Europe Country Selection Criteria Initially create beach head in two most developed ophthalmology regions of the world outside of US: Asia Pacific and Europe Countries with several 1 million+ metro areas Large presbyopia population, high presbyopia per capita Abi

Slide 11: Phase 1 Focus Markets: South Korea & Germany
Phase 1 Focus Markets South Korea & Germany Sustained Resource Concentration – Few countries, more clinics and more customers Multiple refractive practices per metro area to create competition Start lead generation marketing and PR in each metro area Go deep – hands-on with clinic Saturate each city

Slide 12: Surgeon Demand Creation
Surgeon Demand Creation Clinical support = Accelerated commercial growth Surgeon & clinic engagement 5 Ongoing surgeon and clinic support to optimize patient outcomes and enhance commercialization 4 Surgeon certification 3 Wet labs 2 Lead Generation Training Improved Performance Through Higher Close

Slide 13: Patient Demand Creation
Patient Demand Creation Multiple Accounts Per City = Enhanced Penetration & Performance Marketplace Momentum 5 Competition is created between surgeons within individual refractive practices 4 Competition is created between refractive practices 3 Presbia lead generation marketing 2 Consumer PR begins

Slide 14: The LASIK Perspective
The LASIK Perspective Country Population LASIK Cases (2013 Units) LASIK Penetration of Population South Korea 49,000,000 139,000 0.28% Germany 81,000,000 135,000 0.17% LASIK MARKET LASIK is a procedure to eliminate the need for distance glasses. The presbyopia market is approximately 1.6 times the s

Slide 15: Clearly Differentiated Microlens Technology
Clearly Differentiated Microlens Technology

Slide 16: Microlens Surgical Procedure
Microlens Surgical Procedure 10 Minute Procedure Utilizing Existing Femtosecond Laser Femtosecond Laser 1 Creates a pocket in patient’s cornea 3 2 Proprietary Inserters Surgeon uses inserter to implant lens in patient’s cornea Self-Sealing Pocket Pocket self-seals, holding lens in place at center of

Slide 17: Presbia Flexivue Microlens
Intracorneal Refractive Lens implanted in a pocket in cornea of non-dominant eye Hydrophilic Acrylic Material similar to that used in IOLs for > 20 years A True “Microlens” with 3.2 mm diameter and edge thickness of 0.015 mm Offered In A Wide Range Of Powers ranging from +1.5 diopter to +3.5 diopter

Slide 18: Presbia's Microlens Clinical Results
Presbia’s Microlens Clinical Results Average Preop UCVA-near Starting Point = 20/110 Average Postop UCVA-near Ending Point = 20/27 Average 6 Lines of Improvement in Near-Vision Source: Presbia post-market surveillance study (CPL-10-002).

Slide 19: Intellectual Property
Intellectual Property Five patents issued: Lens Holder Apparatus and System Method (US 8,869,975 B2) Lens Inserter Apparatus and Method (US 9,017,401 B2) Lens Injector Apparatus and Method (US 8,454,687 B2) Lens Injector Apparatus System and Method (US 9,010,817 B2) Method for Laser Cutting a Cornea

Slide 20: Clearly Differentiated Microlens Technology
Clearly Differentiated Microlens Technology Intracorneal Refractive Lens; Implanted in a Pocket Creates a Pinhole Effect; Implanted in a Pocket AcuFocus KAMRA Adds Bulk to Cornea; Implanted under a LASIK-like Flap ReVision Optics Raindrop Wide Range of Refractive Powers ü X X Aesthetically Appealing

Slide 21: Manufacturing
Manufacturing Completed construction of 4,000 square-foot, two-part (wet/dry) manufacturing facility in Q3 2013 Approved to manufacture devices for U.S. IDE by State of California FDA in 2013 Sufficient capacity to handle projected Presbia Flexivue Microlens™ volume through U.S. launch Approved to m

Slide 22: Experienced Leadership Team & Board
Experienced Leadership Team & Board Richard Fogarty Chief Accounting Officer & VP Finance Vanessa Tasso Vice President of Clinical Affairs John Strobel Vice President of Sales Vlad Feingold Chief Technology Officer & Director Todd Cooper President, Chief Executive Officer & Director Randy Thurman Ex

Slide 23: Business Highlights
Business Highlights Large, Underserved Presbyopia Opportunity Best-in-Class Microlens Technology Refractive corneal inlay restores reading vision—average 6 lines of improvement Wide range of lens size refractive powers to offer patients a customized therapy Compatible with other ophthalmic surgical

Slide 24: Presbia PLC Contact Information
Presbia PLC (Headquarters) 120-121 Lower Baggot St. Dublin 2, Ireland tel: +353-1-659-9446 Presbia Coöperatief U.A. Pieter Pauwstraat 2A – I · 1017 ZJ Amsterdam, Netherlands tel: +31-20-7084-556 · fax: +31-20-7084-556 PresbiBio LLC 8845 Irvine Center Dr., Suite 100 · Irvine, CA 92618 tel: +1-949‐502
Source: SEC EDGAR · 8-K filed Nov 30, 2015
More decks from Presbia PLC
Investor Presentation (September 2017)16 slides · Sep 8, 2017
Jefferies Healthcare Conference 201717 slides · May 31, 2017
Investor Presentation (September 2016)23 slides · Sep 7, 2016
ESCRS Copenhagen 201613 slides · September 2016
Investor Presentation (July 2016)23 slides · Jul 7, 2016
ROTH Capital Partners Investor Presentation July 201628 slides · Jun 30, 2016